{"acute kidney injury": 2.3, "anaplastic thyroid cancer": 976.14, "blood alkaline phosphatase increased": 2.65, "blood creatine phosphokinase increased": 7.1, "blood lactate dehydrogenase increased": 7.44, "c-reactive protein increased": 3.8, "colitis": 2.17, "dermatitis acneiform": 14.92, "disease progression": 3.36, "drug intolerance": 2.84, "drug reaction with eosinophilia and systemic symptoms": 6.38, "drug resistance": 7.31, "dry skin": 2.03, "dysphagia": 2.16, "ejection fraction decreased": 28.83, "erythema nodosum": 17.0, "general physical health deterioration": 2.43, "haemophagocytic lymphohistiocytosis": 14.81, "hepatic cytolysis": 3.41, "hepatitis": 3.25, "hepatotoxicity": 3.73, "hyperpyrexia": 3.02, "liver function test increased": 2.64, "lung adenocarcinoma": 23.02, "malignant melanoma": 68.1, "malignant melanoma stage iv": 146.73, "malignant neoplasm progression": 24.57, "melanoma recurrent": 111.54, "metastases to bone": 7.22, "metastases to central nervous system": 59.27, "metastases to liver": 10.67, "metastases to lung": 21.5, "metastases to lymph nodes": 22.1, "metastases to meninges": 37.14, "metastases to skin": 67.27, "metastasis": 13.04, "metastatic malignant melanoma": 389.97, "mucosal inflammation": 3.69, "neutropenia": 3.32, "non-small cell lung cancer": 9.98, "panniculitis": 50.57, "peripheral motor neuropathy": 59.38, "peripheral sensory neuropathy": 14.97, "pneumonitis": 5.8, "polyneuropathy": 4.72, "product use in unapproved indication": 9.89, "pulmonary mass": 6.71, "rhabdomyolysis": 5.52, "skin toxicity": 19.85, "therapeutic response decreased": 7.93, "therapy partial responder": 36.94, "toxicity to various agents": 2.04, "uveitis": 31.2}